The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension (SDHDS)
Primary Purpose
Arterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
spironolactone
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Arterial Hypertension focused on measuring hypertension, spironolactone, antihypertensive treatment, Type-2 diabetes
Eligibility Criteria
Inclusion Criteria:
- Age < 75 years
- Type-2 diabetes
- Therapy resistant hypertension (by ABPM)
- Treatment with at least 3 antihypertensives
Exclusion Criteria:
- HbA1c > 10.0
- BP > 180/110 mmHg
- Secondary hypertension
- Intolerance to spironolactone
- Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids
- Total cholesterol 10 mmol/l
- New York Heart Association class III and IV
- Pregnancy or planned pregnancy
- Psychiatric disease
- Malignant disease
- Insufficient adherence
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
addition of spironolactone
Placebo
Arm Description
spironolactone is added to previous antihypertensive treatment
Addition of placebo
Outcomes
Primary Outcome Measures
Change of of Systolic Blood Pressure
Change of systolic blood pressure from baseline to study end at four months.
Change of Diastolic Blood Pressure
Change of diastolic blood pressure from baseline to study end at four months.
Secondary Outcome Measures
Adverse Effects
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01062763
Brief Title
The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
Acronym
SDHDS
Official Title
South Danish Hypertension and Diabetes Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
May 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ib Abildgaard Jacobsen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.
Detailed Description
The primary object of the study is to estimate the effect of addition of low dose spironolactone to antihypertensive treatment with at least three antihypertensive drugs in patients with type-2 diabetes and blood pressure over 130/80 mmHg.
Secondary aims are to estimate how many of these patients have their blood pressure controlled by the addition of spironolactone, to investigate whether the addition of spironolactone affects insulin sensitivity and urinary protein secretion and to estimate the incidence of adverse effects of the aldosterone antagonist.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus
Keywords
hypertension, spironolactone, antihypertensive treatment, Type-2 diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
119 (Actual)
8. Arms, Groups, and Interventions
Arm Title
addition of spironolactone
Arm Type
Experimental
Arm Description
spironolactone is added to previous antihypertensive treatment
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Addition of placebo
Intervention Type
Drug
Intervention Name(s)
spironolactone
Intervention Description
25 to 50 mg once daily
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
addition of placebo 1 to 2 tablets daily
Primary Outcome Measure Information:
Title
Change of of Systolic Blood Pressure
Description
Change of systolic blood pressure from baseline to study end at four months.
Time Frame
4 months
Title
Change of Diastolic Blood Pressure
Description
Change of diastolic blood pressure from baseline to study end at four months.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Adverse Effects
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age < 75 years
Type-2 diabetes
Therapy resistant hypertension (by ABPM)
Treatment with at least 3 antihypertensives
Exclusion Criteria:
HbA1c > 10.0
BP > 180/110 mmHg
Secondary hypertension
Intolerance to spironolactone
Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids
Total cholesterol 10 mmol/l
New York Heart Association class III and IV
Pregnancy or planned pregnancy
Psychiatric disease
Malignant disease
Insufficient adherence
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ib A Jacobsen, DMSc
Organizational Affiliation
Odense University Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
11821720
Citation
Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens. 2002 Feb;20(2):333-8. doi: 10.1097/00004872-200202000-00025.
Results Reference
background
PubMed Identifier
14573330
Citation
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):925-30. doi: 10.1016/s0895-7061(03)01032-x.
Results Reference
background
PubMed Identifier
16814132
Citation
Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006 Jul;19(7):750-5. doi: 10.1016/j.amjhyper.2005.11.016.
Results Reference
background
PubMed Identifier
17309946
Citation
Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007 Apr;49(4):839-45. doi: 10.1161/01.HYP.0000259805.18468.8c. Epub 2007 Feb 19.
Results Reference
background
PubMed Identifier
33107592
Citation
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.
Results Reference
derived
PubMed Identifier
24739800
Citation
Oxlund CS, Cangemi C, Henriksen JE, Jacobsen IA, Gram J, Schousboe K, Tarnow L, Argraves WS, Rasmussen LM. Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension. J Hum Hypertens. 2015 Jan;29(1):28-32. doi: 10.1038/jhh.2014.27. Epub 2014 Apr 17.
Results Reference
derived
Learn more about this trial
The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
We'll reach out to this number within 24 hrs